Epidemiologic Registry PETHEMA LMA 2013
- Conditions
- AML
- Registration Number
- NCT02006004
- Lead Sponsor
- PETHEMA Foundation
- Brief Summary
Epidemiologic and retrospective multicenter registry of all patients diagnosed with de novo or secondary AML in the PETHEMA Group institutions. This study is a non-interventional research regarding diagnosis and therapeutic approach
- Detailed Description
To perform this registry, every patient diagnosed with AML in the participant institutions, regardless type of AML and treatment administered, must be reported. It will be required to registry the main characteristics of the patients and AML at diagnosis, as cytomorphologic, immunophenotypic, and cytogenetic results, according to the habitual practice of the centers. The treatment which has been administered by every center of the PETHEMA Group, even when it is considered as supportive care, and evolution of the disease will also be reported (relapse o death). PETHEMA Group will input all the reported information in data bases with the appropriate security.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1000
Patients diagnosed with acute myeloid leukemia
no exclusion criteria
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Characteristics of the patients diagnosed with AML 3 years To realize an epidemiologic and retrospective study to assess the characteristics of the patients diagnosed with AML and their disease, regardless the age or treatment
- Secondary Outcome Measures
Name Time Method Prognosis factors 3 years To correlate clinical and biological features with outcome and evolution of the patients.
Risk factors 3 years To identify and confirm the risk factors which are involved in the evolution of the disease.
Trial Locations
- Locations (1)
Hospital La Fe
🇪🇸Valencia, Spain